Figure 3.
The clinical course of 14 patients who were retreated with vemurafenib. Patient IDs 2 and 4 were found to have acquired resistance to vemurafenib via CDKN2A loss and activating KRAS mutations, respectively.
The clinical course of 14 patients who were retreated with vemurafenib. Patient IDs 2 and 4 were found to have acquired resistance to vemurafenib via CDKN2A loss and activating KRAS mutations, respectively.
